Cornercap Investment Counsel Inc. Sells 73,786 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Cornercap Investment Counsel Inc. cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 84.6% during the 4th quarter, Holdings Channel reports. The firm owned 13,387 shares of the biopharmaceutical company’s stock after selling 73,786 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Catalyst Pharmaceuticals were worth $225,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Advisory Services Network LLC increased its stake in Catalyst Pharmaceuticals by 260.2% during the 1st quarter. Advisory Services Network LLC now owns 1,801 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 1,301 shares during the period. FMR LLC increased its position in shares of Catalyst Pharmaceuticals by 24.2% in the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 822 shares during the period. Covestor Ltd raised its stake in Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Catalyst Pharmaceuticals by 306.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 3,829 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Catalyst Pharmaceuticals during the first quarter worth about $62,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director David S. Tierney sold 25,000 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 12.10% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Trading Up 3.0 %

NASDAQ:CPRX opened at $16.00 on Thursday. The stock’s 50-day moving average is $15.34 and its 200-day moving average is $14.50. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.09 and a 1-year high of $18.22. The stock has a market cap of $1.89 billion, a P/E ratio of 26.23, a price-to-earnings-growth ratio of 0.85 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. As a group, equities analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CPRX shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. Citigroup started coverage on Catalyst Pharmaceuticals in a report on Thursday, March 14th. They issued a “buy” rating and a $27.00 target price on the stock. StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. HC Wainwright reissued a “buy” rating and set a $24.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Finally, TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $26.43.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.